Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors

Jubber, Ibrahim; Ong, Sean; Bukavina, Laura; Black, Peter C.; Compérat, Éva; Kamat, Ashish M.; Kiemeney, Lambertus A.; Lawrentschuk, Nathan; Lerner, Seth P.; Meeks, Joshua J.; Moch, Holger; Necchi, Andrea; Panebianco, Valeria; Sridhar, Srikala S.; Brennan, Paul; Catto, James W.F.; Cumberbatch, Marcus

doi:10.1016/j.eururo.2023.03.029

Cited by 117 publications

(51 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, the continuous deterioration of the social environment has affected people's physical health, people's lifestyle and dietary structure have been changed, and cancer patients have been increasing year by year 22,23 . Tumors are defined as vegetations that generate space‐occupying lumpy protrusions in patients due to sudden loss of normal regulation of cells in the body due to various carcinogenic factors 24–26 . Most patients with malignant tumors have bad living habits such as smoking, alcoholism, eating high energy and high fat, or malignant tumors in their tissues caused by exogenous factors such as external environmental stimuli, or malignant tumors in their local tissues caused by endogenous factors such as genetic factors, congenital or acquired immunodeficiency, and endocrine disorders 27 .…”

Section: Discussionmentioning

confidence: 99%

Effect of skinfold thickness on arm venous access port in cancer patients

Liu,

Li,

Liu

et al. 2023

Skin Research and Technology

View full text Add to dashboard Cite

BackgroundCurrently, skinfold thickness in studies on arm venous access ports and the effect of venous access port application are unknown.Materials and MethodsA total of 256 cancer patients who underwent primary venous access port placement in the Fourth Hospital of Hebei Medical University from September 2022 to March 2023 were selected as the study subjects. Two hundred fifty‐six patients were divided into normal skinfold thickness group and high skinfold thickness group according to skinfold thickness. The success rate of primary catheterization of arm venous port catheterization, catheterization operation time, catheterization length and incidence rate of adverse reactions were compared.ResultsThere was no significant difference in the basic data between the two groups. There was no significant difference in the success rate of primary catheterization between the two groups (p > 0.05), the catheterization operation time in the normal skinfold thickness group was significantly lower than that in the high skinfold thickness group (p < 0.05), the total length of the implanted catheter in the normal skinfold thickness group was significantly lower than that in the high skinfold thickness group (p < 0.05), and the incidence of adverse reactions in the normal skinfold thickness group was significantly lower than that in the high skinfold thickness group (p < 0.05).ConclusionIn cancer patients, skinfold thickness can significantly affect the application effect of arm venous port, and normal skinfold thickness for arm venous port has shorter operation time, total length of implanted catheter and lower incidence of adverse reactions.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of skinfold thickness on arm venous access port in cancer patients

Liu,

Li,

Liu

et al. 2023

Skin Research and Technology

View full text Add to dashboard Cite

show abstract

“…Currently, smoking is one of the strongest bladder cancer risk factors. Other risk factors include dietary and metabolic factors, genetic alterations, and occupational exposure to carcinogens, such as aromatic hydrocarbons and amines, chlorinated hydrocarbons, inorganic arsenic, and diesel exhaust 3 . Nevertheless, numerous other risk factors remain controversial.…”

Section: Introductionmentioning

confidence: 99%

Examining the causal association between psoriasis and bladder cancer: A two‐sample Mendelian randomization analysis

Du,

Wang,

Wen

et al. 2024

Skin Research and Technology

View full text Add to dashboard Cite

BackgroundPrevious epidemiological observational studies have potentially associated psoriasis with bladder cancer, but the results are inconsistent, and the causality remains unknown. The present study aimed to examine whether there are causal associations between psoriasis and bladder cancer using bidirectional two‐sample Mendelian randomization (MR) analysis.Materials and MethodsA two‐sample MR analysis was conducted using publicly available genome‐wide association study (GWAS) data for individuals diagnosed with psoriasis and bladder cancer. The inverse variance weighted (IVW) method was the primary method. The complementary methods used included the weighted median, MR‐Egger, weighted mode, and simple mode methods. Heterogeneity and pleiotropy of the MR results were detected. Moreover, leave‐one‐out sensitivity analysis was also employed to evaluate the robustness and validity of the findings.ResultsNo significant causal association was detected between psoriasis incidence and the risk of bladder cancer using the IVW method (OR = 0.999, 95% CI 0.977–1.022; P = 0.956). Similarly, the IVW model revealed no evidence of a causal relationship between bladder cancer and the risk of psoriasis (OR = 0.979, 95%CI = 0.873–1.098; P = 0.716). The results of the complementary methods were consistent with those of the IVW method. There was no notable horizontal pleiotropy or heterogeneity (P > 0.05) in our MR analysis. The results of sensitivity analysis confirmed that the MR estimates were not driven by single‐nucleotide polymorphisms (SNPs).ConclusionThis study does not support a causal relationship between psoriasis and bladder cancer.

show abstract

“…Bladder cancer is a common malignancy that is an expensive cancer to treat [1]. In England, over 18,000 people are diagnosed with bladder cancer every year, of which approximately 25% are muscle-invasive bladder cancers (MIBCs) [2].…”

Section: Introductionmentioning

confidence: 99%

Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial

Griffin,

Down,

Quayle

et al. 2024

The Journal of Pathology CR

View full text Add to dashboard Cite

The GUSTO clinical trial (Gene expression subtypes of Urothelial carcinoma: Stratified Treatment and Oncological outcomes) uses molecular subtypes to guide neoadjuvant therapies in participants with muscle‐invasive bladder cancer (MIBC). Before commencing the GUSTO trial, we needed to determine the reliability of a commercial subtyping platform (Decipher Bladder; Veracyte) when performed in an external trial laboratory as this has not been done previously. Here, we report our pre‐trial verification of the TCGA molecular subtyping model using gene expression profiling. Formalin‐fixed paraffin‐embedded tissue blocks of MIBC were used for gene expression subtyping by gene expression microarrays. Intra‐ and inter‐laboratory technical reproducibilities, together with quality control of laboratory and bioinformatics processes, were assessed. Eighteen samples underwent analysis. RNA of sufficient quality and quantity was successfully extracted from all samples. All subtypes were represented in the cohort. Each sample was subtyped twice in our laboratory and once in a separate reference laboratory. No clinically significant discordance in subtype occurred between intra‐ or inter‐laboratory replicates. Examination of sample histopathology showed variability of morphological appearances within and between subtypes. Overall, these results show that molecular subtyping by gene expression profiling is reproducible, robust and suitable for use in the GUSTO clinical trial.

show abstract

Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors

Cited by 117 publications

References 114 publications

Effect of skinfold thickness on arm venous access port in cancer patients

Effect of skinfold thickness on arm venous access port in cancer patients

Examining the causal association between psoriasis and bladder cancer: A two‐sample Mendelian randomization analysis

Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial

Contact Info

Product

Resources

About